Establishment of personalized therapy with epidermal growth factor receptor inhibitors for lung cancer based on the inhibitory effects of surfactant secretion

点击翻译按钮获取中文摘要

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have dramatic effects in selective patients with non-small cell lung cancer. A non-invasive method for predicting the efficacy of EGFR tyrosine kinase inhbitors is needed in clinical settings. The production of surfactant proteins is reported to be regulated through the EGF signaling pathway. The present study suggested that EGFR mutations in the tumor and high levels of serum surfactant protein-D before treatment may predict the efficacy of EGFR tyrosine kinase inhibitors.